total hits: 10
{'took': 7, 'timed_out': False, '_shards': {'total': 1, 'successful': 1, 'skipped': 0, 'failed': 0}, 'hits': {'total': {'value': 1643, 'relation': 'eq'}, 'max_score': 7.98705, 'hits': [{'_index': '2019-trec-precision-medicine', '_type': '_doc', '_id': '249599', '_score': 7.98705, '_source': {'download_date': 'ClinicalTrials.gov processed this data on May 21, 2019', 'url': 'https://clinicaltrials.gov/show/NCT01355120', 'link_text': 'Link to the current ClinicalTrials.gov record.', 'org_study_id': 'DeCOG -MM-PAL11', 'secondary_id': 'NCT01355120', 'nct_id': None, 'brief_title': 'ipi melanoma: melanoma', 'official_title': 'THE IPI - Multibasket Trial in Advanced Melanoma: Prospective Clinical Phase II Multibasket Study in Melanoma Patients With Advanced Disease (DeCOG MM-PAL11)', 'source': 'University Hospital, Essen', 'brief_summary_text_block': 'open-label, multi-center, single-arm characterize ipilimumab pretreatment ocular melanoma. decog-mm-pal11-trial continued ocular melanoma sufficient number cutaneous mucosal melanoma already recruited. separate subgroup ocular melanoma mandatory recruitment guarantee valid cohorts. ocular melanoma melanoma originated uvea, choroid, ciliary conjunctiva. (see mccartney ace "pathology ocular melanomas" british bulltta, 1995, vol 51, pp 678-693) ocular melanoma. exist, 5th criterion adapted enrol', 'detailed_description_text_block': 'treatment: anti-ctla-4 mab ipilimumab monotherapy scope re-induction receipt phase: ipilimumab melanoma medarex mdx-010-20: ipilimumab infusion, mg/kg, (week 1), 22 (week 4), 43 (week 7), 64 (week 10) re-induction: progress progressed (partial complete) offered originally off-treatment met, re-treatment eligibility requirements. re-treated gastrointestinal certain immune-related (irae) (refer section 5.2 5.3). permitted re-treated medication. examinations: responses, thereafter pd year. immune-related (wolchok al., ccr 2009). prematurely discontinued drug-related (in progression) and, appropriate, re-staging assessments. documented re-staging re-induction re-staging visits. phase: ipilimumab patient. fu dose. recruitment finished ensuring estimated. duration: lpfv. recruiting ocular melanoma: recruiting 12-18 enrolment (fpi): qiii 2011 enrolment finish (lpi): qi 2013 study: qi 2014', 'start_date': 'October 2011', 'primary_completion_date': 'September 2012', 'study_type': 'Interventional', 'primary_purpose': 'Single Group Assignment', 'condition': 'Ocular Melanoma', 'intervention_type': 'Drug', 'intervention_name': 'Ipilimumab', 'gender': 'All', 'minimum_age': '18 Years', 'maximum_age': 'N/A', 'last_name': 'Dirk Schadendorf, Professor', 'affiliation': 'University Hospital, Essen', 'country': 'Germany', 'verification_date': 'June 2014', 'study_first_submitted': 'December 29, 2010', 'study_first_submitted_qc': 'May 16, 2011', 'last_update_posted': 'June 23, 2014', 'keyword': 'advanced ocular melanoma', 'mesh_term': 'Melanoma', 'intervention_browse_0_mesh_term': 'Ipilimumab', 'intervention_browse_1_mesh_term': None}}, {'_index': '2019-trec-precision-medicine', '_type': '_doc', '_id': '5825', '_score': 7.697505, '_source': {'download_date': 'ClinicalTrials.gov processed this data on May 21, 2019', 'url': 'https://clinicaltrials.gov/show/NCT00023647', 'link_text': 'Link to the current ClinicalTrials.gov record.', 'org_study_id': 'CDR0000068847', 'secondary_id': 'CTL-207-216', 'nct_id': 'NCI-V01-1666', 'brief_title': 'melanoma', 'official_title': 'A Phase I Dose-Ranging Safety Study Using Intranodal Delivery of a Plasmid DNA (Synchrotope TA2M) in Adult Stage IV Melanoma Patients', 'source': 'Mannkind Corporation', 'brief_summary_text_block': 'rationale: vaccine build kill infusing directly lymph node stronger kill purpose: directly lymph node melanoma.', 'detailed_description_text_block': 'intranodal synchrotope ta2m plasmid melanoma. ii. vaccine. iii. vaccine. dose-escalation, multicenter synchrotope ta2m plasmid intranodally continuously 96 0, 14, 28, 42. continues cohort escalating synchrotope ta2m plasmid (mtd) determined. mtd dose-limiting projected accrual: 16-24 accrued', 'start_date': 'July 2000', 'primary_completion_date': 'April 2002', 'study_type': 'Interventional', 'primary_purpose': 'Single Group Assignment', 'condition': 'Melanoma (Skin)', 'intervention_type': 'Biological', 'intervention_name': 'Synchrotope TA2M', 'gender': 'All', 'minimum_age': '18 Years', 'maximum_age': 'N/A', 'last_name': 'Barbara Hickingbottom, JD, MD', 'affiliation': 'Mannkind Corporation', 'country': 'United States', 'verification_date': 'July 2012', 'study_first_submitted': 'September 13, 2001', 'study_first_submitted_qc': 'February 13, 2004', 'last_update_posted': 'July 10, 2012', 'keyword': 'recurrent melanoma', 'mesh_term': 'Melanoma', 'intervention_browse_0_mesh_term': 'Vaccines', 'intervention_browse_1_mesh_term': None}}, {'_index': '2019-trec-precision-medicine', '_type': '_doc', '_id': '5449', '_score': 7.697505, '_source': {'download_date': 'ClinicalTrials.gov processed this data on May 21, 2019', 'url': 'https://clinicaltrials.gov/show/NCT00020475', 'link_text': 'Link to the current ClinicalTrials.gov record.', 'org_study_id': 'CDR0000068514', 'secondary_id': 'NCI-01-C-0074', 'nct_id': 'NCT00009516', 'brief_title': 'melanoma', 'official_title': 'Phase II Study of gp100:209-217 (210M) Antigen and MART-1:26-35 (27L) Antigen Emulsified in Montanide ISA-51 in Patients With Metastatic Ocular Melanoma', 'source': 'National Cancer Institute (NCI)', 'brief_summary_text_block': 'rationale: vaccine build kill combining interleukin-2 melanoma eye. purpose: interleukin-2 melanoma eye.', 'detailed_description_text_block': 'ocular melanoma gp100:209-217 (210m) antigen mart-1:26-35 (27l) antigen emulsified montanide isa-51. ii. interleukin-2 subcutaneously weekly. repeat progressive sc interleukin-2 doses. repeat projected accrual: 15-25 accrued year.', 'start_date': 'February 2001', 'primary_completion_date': None, 'study_type': 'Interventional', 'primary_purpose': 'Treatment', 'condition': 'Recurrent Intraocular Melanoma', 'intervention_type': 'Drug', 'intervention_name': 'Montanide ISA-51', 'gender': 'All', 'minimum_age': '16 Years', 'maximum_age': 'N/A', 'last_name': 'Francesco M. Marincola', 'affiliation': 'National Cancer Institute (NCI)', 'country': 'United States', 'verification_date': 'July 2002', 'study_first_submitted': 'March 2, 2007', 'study_first_submitted_qc': 'March 2, 2007', 'last_update_posted': 'August 16, 2013', 'keyword': 'stage, intraocular melanoma', 'mesh_term': 'Melanoma', 'intervention_browse_0_mesh_term': 'Interleukin-2', 'intervention_browse_1_mesh_term': "Freund's Adjuvant"}}, {'_index': '2019-trec-precision-medicine', '_type': '_doc', '_id': '5491', '_score': 7.697505, '_source': {'download_date': 'ClinicalTrials.gov processed this data on May 21, 2019', 'url': 'https://clinicaltrials.gov/show/NCT00020397', 'link_text': 'Link to the current ClinicalTrials.gov record.', 'org_study_id': 'CDR0000068403', 'secondary_id': 'NCI-01-C-0032', 'nct_id': 'NCT00006491', 'brief_title': 'melanoma', 'official_title': 'Immunization Of HLA-A*0201 or HLA-DPB1*04 Patients With Metastatic Melanoma Using Epitopes From The ESO-1 Antigen', 'source': 'National Cancer Institute (NCI)', 'brief_summary_text_block': 'rationale: vaccine build kill purpose: melanoma.', 'detailed_description_text_block': 'immunologic eso-1 peptide comprising class ii, peptide hla-a*201 hla-dpb1*04 melanoma expressing eso-1. immunization responsiveness interleukin-2. hla type. (hla-a*201 hla-dpb1*04 positive): eso-1 peptide comprising class (eso-1:157-165 [165v]) class (eso-1:161-180) peptide subcutaneously (hla-a*201 hla-dpb1*04 negative):patients eso-1 peptide comprising class peptide only. (hla-a*201 hla-dpb1*04 positive):patients eso-1 peptide comprising class peptide only. discontinue vaccination high-dose interleukin (il-2) (maximum doses). il-2 repeat 10-14 (after courses) mixed il-2 projected accrual: 45-90 (15-30 group) accrued year.', 'start_date': 'November 2000', 'primary_completion_date': None, 'study_type': 'Interventional', 'primary_purpose': 'Treatment', 'condition': 'Melanoma (Skin)', 'intervention_type': 'Biological', 'intervention_name': 'aldesleukin', 'gender': 'All', 'minimum_age': '16 Years', 'maximum_age': 'N/A', 'last_name': 'Steven A. Rosenberg, MD, PhD', 'affiliation': 'NCI - Surgery Branch', 'country': 'United States', 'verification_date': 'January 2005', 'study_first_submitted': 'July 11, 2001', 'study_first_submitted_qc': 'January 26, 2003', 'last_update_posted': 'June 19, 2013', 'keyword': 'stage IV melanoma', 'mesh_term': 'Melanoma', 'intervention_browse_0_mesh_term': 'Vaccines', 'intervention_browse_1_mesh_term': 'Aldesleukin'}}, {'_index': '2019-trec-precision-medicine', '_type': '_doc', '_id': '5495', '_score': 7.697505, '_source': {'download_date': 'ClinicalTrials.gov processed this data on May 21, 2019', 'url': 'https://clinicaltrials.gov/show/NCT00020358', 'link_text': 'Link to the current ClinicalTrials.gov record.', 'org_study_id': 'CDR0000068299', 'secondary_id': 'NCI-00-C-0216', 'nct_id': 'NCT00006287', 'brief_title': 'melanoma', 'official_title': 'Randomized Comparison of Three Schedules of Peptide Immunization in Patients With Stage II or III, or Completely Resected Metastatic Melanoma', 'source': 'National Cancer Institute (NCI)', 'brief_summary_text_block': 'rationale: vaccine build kill melanoma. purpose: regimen melanoma.', 'detailed_description_text_block': 'immunologic schedule peptide immunization gp100:209-217 (210m) gp100:17-25 antigen tyrosinase:368-376 (370d), tyrosinase:240-251 (244s), tyrosinase:206-214 (closed accrual 11/05/01), tyrosinase-related protein-1 (orf3):1-9 peptide (closed accrual 11/05/01) emulsified montanide isa-51 melanoma recurrence. interleukin-2 (il-2) immunized il-2 exploratory hla-a2-positive immunologic immunization peptide emulsified together. stratified hla (a0201 a1 a3 a24 a31). (hla-a24 hla-a31 closed accrual 11/05/01). arm vaccine, emulsified montanide isa-51. hla typing: hla-a2: gp100:209-217 (210m) tyrosinase:368-376 (370d) hla-a1: tyrosinase:240-251 (244s) hla-a3: gp100:17-25 hla-a24: tyrosinase:206-214 (closed accrual 11/05/01) hla-a31: tyrosinase-related protein-1 (orf3):1-9 (closed accrual 11/05/01) i: subcutaneously (sc) ii: sc 22, 43, 64. iii: sc 1-4, 22-25, 43-46, 64-67. arm repeat 13 arm hla-a2 hla-a2 immunization gp100:209-217 (210m) tyrosinase:368-376 (370d) emulsified montanide isa-51 sc courses. progressive interleukin-2 repeat 10-14 mixed projected accrual: 324 (19-33 hla-a0201 stratum, 13-16 strata, 33 hla-a2 cohort) accrued (hla-a24 hla-a31 closed accrual 11/05/01).', 'start_date': 'September 2000', 'primary_completion_date': None, 'study_type': 'Interventional', 'primary_purpose': 'Randomized', 'condition': 'Melanoma (Skin)', 'intervention_type': 'Biological', 'intervention_name': 'tyrosinase peptide', 'gender': 'All', 'minimum_age': '16 Years', 'maximum_age': 'N/A', 'last_name': 'Steven A. Rosenberg, MD, PhD', 'affiliation': 'NCI - Surgery Branch', 'country': 'United States', 'verification_date': 'March 2003', 'study_first_submitted': 'July 11, 2001', 'study_first_submitted_qc': 'January 26, 2003', 'last_update_posted': 'June 19, 2013', 'keyword': 'recurrent melanoma', 'mesh_term': 'Melanoma', 'intervention_browse_0_mesh_term': 'Aldesleukin', 'intervention_browse_1_mesh_term': "Freund's Adjuvant"}}, {'_index': '2019-trec-precision-medicine', '_type': '_doc', '_id': '5279', '_score': 7.697505, '_source': {'download_date': 'ClinicalTrials.gov processed this data on May 21, 2019', 'url': 'https://clinicaltrials.gov/show/NCT00022568', 'link_text': 'Link to the current ClinicalTrials.gov record.', 'org_study_id': 'CDR0000068831', 'secondary_id': 'CPMC-IRB-14387', 'nct_id': 'NCT00022568', 'brief_title': 'melanoma', 'official_title': 'A Phase I Trial of Intra Lesional rV-Tricom Vaccine in the Treatment of Malignant Melanoma', 'source': 'National Cancer Institute (NCI)', 'brief_summary_text_block': 'rationale: vaccine build kill purpose: melanoma.', 'detailed_description_text_block': 'recombinant vaccinia-tricom melanoma. toxic vaccine. host anti-melanoma reactivity vaccine. dose-escalation recombinant vaccinia-tricom vaccinations. responding vaccinations. cohort 3-6 escalating recombinant vaccinia-tricom (mtd) determined. mtd preceding dose-limiting administration, completion. projected accrual: 12-18 accrued 6-12', 'start_date': 'August 2001', 'primary_completion_date': None, 'study_type': 'Interventional', 'primary_purpose': 'Treatment', 'condition': 'Melanoma (Skin)', 'intervention_type': 'Biological', 'intervention_name': 'recombinant vaccinia-TRICOM vaccine', 'gender': 'All', 'minimum_age': '18 Years', 'maximum_age': 'N/A', 'last_name': 'Howard L. Kaufman, MD', 'affiliation': 'Herbert Irving Comprehensive Cancer Center', 'country': 'United States', 'verification_date': 'December 2003', 'study_first_submitted': 'August 10, 2001', 'study_first_submitted_qc': 'January 26, 2003', 'last_update_posted': 'December 18, 2013', 'keyword': 'recurrent melanoma', 'mesh_term': 'Melanoma', 'intervention_browse_0_mesh_term': 'Vaccines', 'intervention_browse_1_mesh_term': 'Metronidazole'}}, {'_index': '2019-trec-precision-medicine', '_type': '_doc', '_id': '5365', '_score': 7.697505, '_source': {'download_date': 'ClinicalTrials.gov processed this data on May 21, 2019', 'url': 'https://clinicaltrials.gov/show/NCT00020540', 'link_text': 'Link to the current ClinicalTrials.gov record.', 'org_study_id': 'CDR0000068601', 'secondary_id': 'NCI-01-C-0121', 'nct_id': 'NCT00012532', 'brief_title': 'melanoma', 'official_title': 'Treatment Of Patients With Metastatic Melanoma And Renal Cancer With A Combination Of Flt3L And CD40L', 'source': 'National Cancer Institute (NCI)', 'brief_summary_text_block': 'rationale: therapy flt3l cd40-ligand way stimulate growing. melanoma purpose: flt3l cd40-ligand melanoma', 'detailed_description_text_block': 'cd40-ligand fixed-dose flt3 ligand melanoma dose-escalation cd40-ligand. fixed-dose flt3 ligand subcutaneously (sc) 1-14 cd40-ligand sc 12-16. continues progression. cohort escalating cd40-ligand (mtd) determined. mtd preceding dose-limiting progressive high-dose interleukin-2 (il-2) projected accrual: accrued', 'start_date': 'March 2001', 'primary_completion_date': None, 'study_type': 'Interventional', 'primary_purpose': 'Treatment', 'condition': 'Melanoma (Skin)', 'intervention_type': 'Biological', 'intervention_name': 'recombinant flt3 ligand', 'gender': 'All', 'minimum_age': '16 Years', 'maximum_age': 'N/A', 'last_name': 'Patrick Hwu, MD', 'affiliation': 'NCI - Surgery Branch', 'country': 'United States', 'verification_date': 'April 2002', 'study_first_submitted': 'July 11, 2001', 'study_first_submitted_qc': 'April 2, 2004', 'last_update_posted': 'April 30, 2015', 'keyword': 'recurrent melanoma', 'mesh_term': 'Melanoma', 'intervention_browse_0_mesh_term': 'Flt3 ligand protein', 'intervention_browse_1_mesh_term': None}}, {'_index': '2019-trec-precision-medicine', '_type': '_doc', '_id': '76356', '_score': 7.697505, '_source': {'download_date': 'ClinicalTrials.gov processed this data on May 21, 2019', 'url': 'https://clinicaltrials.gov/show/NCT00705640', 'link_text': 'Link to the current ClinicalTrials.gov record.', 'org_study_id': '13498', 'secondary_id': 'R01CA057653', 'nct_id': 'UVACC-IRB-13498', 'brief_title': 'melanoma', 'official_title': 'A Multipeptide Vaccine in Melanoma Patients With Evaluation of the Injection Site Microenvironment', 'source': 'University of Virginia', 'brief_summary_text_block': 'rationale: build kill purpose: studying work melanoma.', 'detailed_description_text_block': "circulating cd8 t-cell multipeptide melanoma. immunization peptide incomplete freund's adjuvant induces lymph-node-like aggregate (lnla) tertiary lymphoid organ (tlos) extended immunization (vaccinations 4-6) immune-regulatory process microenvironment/tlo. characterize peptide-reactive cd4 cd8 loco immunization multipeptide vaccine. characterize toll-like receptor 7, 9, myd88 dendritic infiltrating vaccination vaccination. arms. comprising melanoma multipeptides tetanus toxoid helper peptide emulsified incomplete freund's adjuvant, subcutaneously (sc) intradermally (id), 15, 29, 36, 43. vaccine location extremity uninvolved melanoma. replicate replica administration. 1a: replicate vaccine. replicate 1b: replicate comprising incomplete freund's adjuvant sc id replicate (1 replicate 1). 1c: replicate comprising incomplete freund's adjuvant sc id replicate 22 (1 replicate 3). 1d: replicate comprising incomplete freund's adjuvant sc id 15, 29, 36, 43 replicate (1 replicate 6). 1-3 biopsy. 1e: replicate comprising incomplete freund's adjuvant sc id 15, 29, 36, 43 replicate 85 (6 replicate 6). 1-3 biopsy. 2a: replicate vaccine. replicate 2b: replicate (the vaccine) sc id replicate (1 replicate 1). 2c: replicate (the vaccine) sc id replicate 22 (1 replicate 3). 2d: replicate (the vaccine) sc id 15, 29, 36, 43 replicate (1 replicate 6). 1-3 biopsy. 2e: replicate (the vaccine) sc id 15, 29, 36, 43 replicate 85 (1 replicate 6). 1-3 biopsy. biopsy examined reverse transcriptase-pcr, ihc, analysis, cytometry, western blot. periodically examined elispot assay, tetramer staining, proliferation assay. annually.", 'start_date': 'May 2008', 'primary_completion_date': 'June 2009', 'study_type': 'Interventional', 'primary_purpose': 'Randomized', 'condition': 'Melanoma (Skin)', 'intervention_type': 'Procedure', 'intervention_name': 'biopsy', 'gender': 'All', 'minimum_age': '18 Years', 'maximum_age': '120 Years', 'last_name': 'Craig L. Slingluff, MD', 'affiliation': 'University of Virginia', 'country': 'United States', 'verification_date': 'December 2016', 'study_first_submitted': 'June 25, 2008', 'study_first_submitted_qc': 'June 25, 2008', 'last_update_posted': 'December 16, 2016', 'keyword': 'recurrent intraocular melanoma', 'mesh_term': 'Melanoma', 'intervention_browse_0_mesh_term': 'Vaccines', 'intervention_browse_1_mesh_term': "Freund's Adjuvant"}}, {'_index': '2019-trec-precision-medicine', '_type': '_doc', '_id': '75094', '_score': 7.697505, '_source': {'download_date': 'ClinicalTrials.gov processed this data on May 21, 2019', 'url': 'https://clinicaltrials.gov/show/NCT00045357', 'link_text': 'Link to the current ClinicalTrials.gov record.', 'org_study_id': '1585.00', 'secondary_id': 'FHCRC-1585.00', 'nct_id': 'NCT00045357', 'brief_title': 'melanoma', 'official_title': 'Phase I Study to Evaluate the Safety of Cellular Adoptive Immunotherapy Using Autologous CD4+ Antigen-Specific T Cell Clones for Patients With Metastatic Melanoma', 'source': 'Fred Hutchinson Cancer Research Center', 'brief_summary_text_block': "rationale: therapy way stimulate growing. person's white reinfusing stronger kill purpose: melanoma.", 'detailed_description_text_block': 'autologous cd4+ antigen-specific t-cells cellular adoptive immunotherapy melanoma. vivo persistence adoptively transferred cd4+ antigen-specific t-cell clone antitumor dose-escalation leukapheresis mononuclear cd4+ antigen-specific t-cell clone generated 2-3 immunogenic peptide mart1, tyrosinase, gp100. autologous cd4+ antigen-specific t-cells minutes. cohort 3-6 escalating autologous cd4+ antigen-specific t-cells (mtd) determined. mtd preceding dose-limiting t-cell infusion, projected accrual: 3-18 accrued', 'start_date': 'November 2001', 'primary_completion_date': None, 'study_type': 'Interventional', 'primary_purpose': 'Treatment', 'condition': 'Melanoma (Skin)', 'intervention_type': 'Biological', 'intervention_name': 'therapeutic autologous lymphocytes', 'gender': 'All', 'minimum_age': '18 Years', 'maximum_age': '75 Years', 'last_name': 'Cassian Yee, MD', 'affiliation': 'Fred Hutchinson Cancer Research Center', 'country': 'United States', 'verification_date': 'September 2010', 'study_first_submitted': 'September 6, 2002', 'study_first_submitted_qc': 'July 7, 2003', 'last_update_posted': 'September 21, 2010', 'keyword': 'stage IV melanoma', 'mesh_term': 'Melanoma', 'intervention_browse_0_mesh_term': None, 'intervention_browse_1_mesh_term': None}}, {'_index': '2019-trec-precision-medicine', '_type': '_doc', '_id': '75243', '_score': 7.697505, '_source': {'download_date': 'ClinicalTrials.gov processed this data on May 21, 2019', 'url': 'https://clinicaltrials.gov/show/NCT00049010', 'link_text': 'Link to the current ClinicalTrials.gov record.', 'org_study_id': 'CALGB-500105', 'secondary_id': 'U10CA031946', 'nct_id': 'NCT00049010', 'brief_title': 'melanoma', 'official_title': 'Prospective Study of Melastatin Expression in Predicting the Risk for Developing Local Regional Metastases of Primary Melanoma', 'source': 'Alliance for Clinical Trials in Oncology', 'brief_summary_text_block': 'rationale: analyze surgically-removed lymph node doctor melanoma purpose: studying lymph node predicting melanoma.', 'detailed_description_text_block': 'correlate melastatin regional metastasis melanoma. correlate melastatin prospectively event-free multicenter melastatin mrna situ hybridization lymph nodes. examined immunohistochemical staining antibody s-100 mart-1. 3.5 projected accrual: 300 accrued 3.5', 'start_date': 'September 2002', 'primary_completion_date': 'March 2006', 'study_type': 'Interventional', 'primary_purpose': 'Non-Randomized', 'condition': 'Melanoma (Skin)', 'intervention_type': 'Other', 'intervention_name': 'immunohistochemistry staining method', 'gender': 'All', 'minimum_age': '18 Years', 'maximum_age': 'N/A', 'last_name': 'F. Stephen Hodi, MD', 'affiliation': 'Dana-Farber Cancer Institute', 'country': 'United States', 'verification_date': 'June 2016', 'study_first_submitted': 'November 12, 2002', 'study_first_submitted_qc': 'January 26, 2003', 'last_update_posted': 'July 1, 2016', 'keyword': 'stage II melanoma', 'mesh_term': 'Melanoma', 'intervention_browse_0_mesh_term': None, 'intervention_browse_1_mesh_term': None}}]}}
